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RatAsthma is an allergic lung disease can be modulated by drugs that modify the activity of central nervous sys-
tem (CNS) such as amphetamine (AMPH). AMPH is a highly abused drug that exerts potent effects on behav-
ior and immunity. In this study we investigated the mechanism involved in the effects of long-term AMPH
treatment on the increased magnitude of allergic lung response. We evaluated mast cells degranulation, cy-
tokines release, airways responsiveness and, expression of adhesion molecules. MaleWistar rats were treated
with AMPH or vehicle (PBS) for 21 days and sensitized with ovalbumin (OVA) one week after the ﬁrst injec-
tion of vehicle or AMPH. Fourteen days after the sensitization, the rats were challenged with an OVA aerosol,
and 24 h later their parameters were analyzed. In allergic rats, the treatment with AMPH exacerbated the
lung cell recruitment due increased expression of ICAM-1, PECAM-1 and Mac-1 in granulocytes and macro-
phages recovered from bronchoalveolar lavage. Elevated levels of IL-4, but decreased levels of IL-10
were also found in samples of lung explants after AMPH treatment. Conversely, the ex-vivo tracheal
hyper-responsiveness to methacholine (MCh) was reduced by AMPH treatment, whereas the force contrac-
tion of tracheal segments due to in vitro antigen challenge remained unaltered.
Our ﬁndings suggest that lung inﬂammation and airway hyper-responsiveness due to OVA challenge are
under the distinct control of AMPH during long-term treatment. Our data strongly indicate that AMPH pos-
itively modulates allergic lung inﬂammation via the increase of ICAM-1, PECAM-1, Mac-1 and IL-4. AMPH
also abrogates the release of the anti-inﬂammatory cytokine IL-10.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Several environmental chemicals and drugs that act on the CNS such
as amphetamine (AMPH) are recognized as potential immunotoxicants.
The clinical use of AMPH is presently restricted to the treatment of par-
ticular disorders such as attention deﬁcit disorder, narcolepsy and obe-
sity [1]. However, AMPH is a widely abused recreational drug [2,3] and,
induces chemical dependence [4]. AMPH has potent effects on the CNS
and can also induce behavioral and immune alterations [5]. Studies ofne, Laboratory of Applied Phar-
f. Dr. OrlandoMarques de Paiva,
, Brazil. Tel.: +55 11 30917957;
evier OA license.our group and others have revealed that AMPH interferes with the
hypothalamo-pituitary axis (HPA) bymodulating the secretion of corti-
costerone, one of the mechanisms by which AMPH regulates allergic
lung inﬂammation, including asthma [6–8].
Asthma is a chronic inﬂammatory disorder, characterized by,
among other characteristics, pulmonary cellular inﬁltration and air-
way hyper-responsiveness. The incidence of asthma has increased
greatly in the last few decades [9]. Varying degrees of mononuclear
cell and eosinophil inﬁltration, mucus hypersecretion, epithelium
desquamation, smooth muscle hyperplasia and airway remodeling
have been reported in asthma patients [10].
In previous studies, we showed that the development of allergic
lung inﬂammation can be suppressed by a single treatment with
AMPH before OVA challenge. This effect is mediated by increased cor-
ticosterone production, which subsequently reduces cytokine release
and the expression of adhesion molecules on the lung tissue [6,11].
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Fig. 1. Effects of long-term amphetamine treatment on allergic lung inﬂammation.
Group of rats were treated with amphetamine (AMPH, 1 mg/kg, ip) or vehicle (PBS,
ip), once a day, for 21 consecutive days, and sensitized with ovalbumin (OVA) one
week after the ﬁrst injection of vehicle or AMPH. Seven days after the sensitization,
the rats were challenged with OVA by aerosol. Lung inﬂammation was assessed by
the quantiﬁcation of recruited cells present in the bronchoalveolar lavage (BAL)
24 hours after the OVA aerosol challenge. The control group consisted of
non-manipulated rats (naive group). Panel A represents the number of total cells,
whereas panel B represents the number of differential cells. Data are the mean±
SEM from 5 animals. *pb0.05 relative to naive group and ϕpb0.05 relative to allergic
group (ANOVA followed by Student–Newman–Keuls test).
524 A.P. Ligeiro de Oliveira et al. / International Immunopharmacology 14 (2012) 523–529On the other hand, utilizing a different protocol, we found that re-
peated (21 days) AMPH treatment exacerbated the lung inﬂammato-
ry response of allergic rats, an effect not detected 72 and 120 h after
abrupt withdrawal [6].
Because AMPH is an abused drug that induces chemical dependence
and in previous studies we found that repeated AMPH treatment exac-
erbates the allergic lung inﬂammation, in the present work we investi-
gated the mechanism involved in the effects of long-term AMPH
treatment on the increased magnitude of allergic lung response. Ac-
cordingly, we examined themodulatory role of AMPH on important pa-
rameters that regulate the allergic response, including mast cells
degranulation, cytokines release, airways responsiveness and, expres-
sion of adhesion molecules. The data obtained reinforce the relevance
of studies that associate abused drugs and airway diseases as a public
health problem.
2. Materials and methods
2.1. Animals
Male Wistar rats (180–200 g) from our departmental facilities
were used. The animals were maintained under controlled tempera-
ture (21–23 °C) and 12 h light/12 h dark cycle conditions with free
access to food and water. They were housed in plastic cages and han-
dled in accordance with the guidelines of the Bioethical Committee of
Care and Use of Laboratory Animal Resources of the School of Veteri-
nary Medicine, University of São Paulo.
2.2. Amphetamine treatment
Amphetamine sulfate (Sigma Chemical Company®, USA) was ad-
ministered long-term intraperitoneally (i.p.) at a dose of 1.0 mg/kg
once a day for 21 consecutive days. The control groups were treated
with PBS (AMPH vehicle). This dose of AMPH was chosen because it
has been shown to induce anxiety-like symptoms [12]. In addition,
the dosage used has been shown to decrease hamster resistance to
Mycobacterium bovis infection [13] and the number of lung inﬂamma-
tory cells and blood leukocytes in OVA-sensitized and challenged rats
(OVA grade II, Sigma Company®, USA) [7].
2.3. Sensitization procedures
Rats were sensitized by subcutaneous injection of a suspension of
10 μg of ovalbumin (OVA) with 10 mg of aluminum hydroxide (day 0).
Oneweek later (day 7), the rats received 10 μg of OVAdissolved in saline
by subcutaneous injection (booster). At day 14, the animals were
subjected to a single 15-min exposure of aerosolized OVA (1% in
phosphate-buffered saline, PBS) using an ultrasonic nebulizer device
(Icel®, SP, Brazil) coupled to a plastic inhalation chamber (18.5 cm×
18.5 cm×13.5 cm).
2.4. Experimental design
The experiments were performed in accordance with good labora-
tory practice and quality assurance methods.
Adult (60 days old) male rats were randomly assigned to 3 groups.
The rats of the ﬁrst group (allergic)were treatedwith the AMPH vehicle
(PBS) for 21 consecutive days. OVA sensitization was performed one
week after the ﬁrst injection of vehicle. Fourteen days after the sensiti-
zation, the rats were challenged with OVA by aerosol (see protocol
above). The second group (allergic+AMPH) ratswere treatedwith am-
phetamine for 21 consecutive days and sensitized with ovalbumin
(OVA) one week after the ﬁrst injection of AMPH. One week after the
ﬁrst injection, the rats were subjected to an OVA aerosol challenge.
The third group rats (naïve, non-manipulated rats) were used to inves-
tigate basal parameters. These rats were euthanized by sectioning theabdominal aorta under deep chloral hydrate anesthesia (>400 mg/kg,
i.p.) 24 h after the OVA challenge.
2.5. Bronchoalveolar lavage (BAL)
BAL ﬂuid was taken from sacriﬁced animals according to the proce-
dure described by De Lima et al. [14]. The trachea was cannulated with
a polyethylene tube (1-mm inner diameter) and the lungs were washed
by ﬂushing with PBS (20 ml). The recovered BAL ﬂuid was centrifuged
(170 ×g for 10 min at 20 °C), and the resulting cell pellet was then
re-suspended in PBS (1 ml). Cell suspensions (90 μl) were stained with
10 μl of 0.2% crystal violet, and the total cell number was determined in
Neubauer chambers. The differential cell counts were carried out with
cytocentrifuge preparations (Cytospin®, Fanem, Brazil) stained with
May–Grünwald–Giemsa solution.
2.6. Determination of cytokines in lung explants
Interleukin-10, 4 and tumor necrosis factor alpha (TNF-α) levels
were determined for samples of supernatants of lung explants
maintained in culture [15]. Brieﬂy, the lungs of the studied groups
of rats were ﬂushed through the right heart with 5 ml of PBS to
remove the intravascular blood. The remaining parenchyma was
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Fig. 2. Cytokines IL-4 (A), IL-10 (B) and TNF-α (C) levels released by lungs in explant cul-
ture after long-term AMPH treatment. One group of rats were OVA-sensitized and then
OVA-challenged 14 days after the start of the experiment (Allergic group). In a parallel
set of experiments, a group of rats were long-term treated with AMPH (1 mg/kg) one
weekbeforeOVA-sensitization, once a day, for 21 days (Allergic+AMPHgroup). The con-
trol group consisted of non-manipulated rats (Naïve). Twenty-four hours after
OVA-challenge, the cytokines were quantiﬁed by ELISA. Data are the mean±SEM from
5 animals. *pb0.05 relative to naive group and ϕpb0.05 relative to allergic group
(ANOVA followed by Student–Newman–Keuls test).
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into 24-well plates ﬁlled with 1 ml of Dulbecco's modiﬁed Eagle's me-
dium (DMEM) containing 0.5% penicillin-streptomycin (10.000 UI —
10 mg/ml) and incubated for 24 h at 37 °C with 5% CO2. The results
were expressed as pg of cytokine produced per mg of dry-weight
lung tissue. All determinations were made using standard curves
according to the manufacturer's speciﬁcations.
2.7. Flow cytometry
BAL cells were resuspended in Dulbecco's modiﬁed Eagle's medi-
um (DMEM) containing 2% FCS. After BAL ﬂuid centrifugation, the
cells were recovered after washing with Hank's balanced salt solution
(HBSS). To quantify the expression of adhesion molecules, leukocytes
(1×105) were incubated for 20 min in the dark at 4 °C with 100 μl of
1:100 monoclonal antibody dilution (Ly6G or F4/80 conjugated with
FITC and Mac-1, ICAM-1 or PECAM-1 conjugated with PE). After
that, the cells were analyzed in a FACS Calibur ﬂow cytometer (Becton
& Dickinson, San Jose, CA, USA). Data from 10,000 events were
obtained and only the morphologically viable leukocytes were con-
sidered for analysis. The results are presented as arbitrary units of
ﬂuorescence and marked cells percentage.2.8. Tracheal responsiveness tomethacholine (MCh) and anaphylaxis in vitro
Tracheal rings were mounted for the measurement of isometric
force quantiﬁcation by means of two steel hooks in a 30-ml organ
bath [16]. Force contraction was registered using a force displacement
transducer and a chart recorder (Powerlab®, Labchart, AD Instru-
ments). Brieﬂy, the tracheal rings were suspended in an organ bath
ﬁlled with KH at 37 °C. The tissues were continuously aerated (95%
O2 and 5% CO2) and after the equilibrium period (40 min), the trache-
al tension was adjusted to 1 g. Tissue viabilities were assessed by
replacing KH solution with KCl buffer (60 mM) in the bath and com-
paring the contraction force generated with those obtained previous-
ly. Next, cumulative dose–response curves to methacholine (MCh)
were constructed [17]. In a parallel set of experiments, we evaluated
the effects of AMPH on mast cell degranulation. For this purpose, the
Shultz–Dale reaction was performed. After the equilibrium period
(40 min), an ovalbumin solution (4 mg/ml) was added to a 30-ml
organ bath and the contraction force was measured.
2.9. Histological analysis
Rat lungs were excised before being ﬁxed in 2% paraformaldehyde
and 2% glutaraldehyde in 0.1 M sodium phosphate buffer (pH 7.4) for
24 h at 4 °C. Next, they were fragmented, washed, dehydrated in etha-
nol, clariﬁed in xylene and embedded in Histosec™ (MERK, USA). Sec-
tions were cut (3 μm; HYRAX M60, Zeiss, GR), mounted on slides, and
stained with 0.25% toluidine blue and 0.25% borate sodium solution.
The quantiﬁcation of mast cell number and activation in tissue samples
was performed with a high-power objective (×40) by measuring the
area of analysis with the Axiovision software (Zeiss, GR). Data were
reported as cells/mm2 (analyzing at least 10 distinct sections per rat).
2.10. Statistical analysis
Data are expressed as means±SEM, and comparisons among the
experimental groups were analyzed by one-way ANOVA followed
by the Student–Newman–Keuls test for multiple comparisons using
GraphPad software V.2.01, GraphPad Instat™ (1990–1993). p-Values
less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Effect of long-term treatment with amphetamine on allergic lung
inﬂammation induced by OVA challenge
A signiﬁcant increase in the number of leukocytes was observed in
the BAL ﬂuid of the allergic group when compared to the naïve group.
However, the treatment with AMPH caused a signiﬁcant increase in
the number of leukocytes recovered in BAL compared to the allergic
and naïve groups (Fig. 1, panel A). Differential cell analyses indicated
that the OVA challenge increased the number of recruited lymphocytes,
neutrophils and eosinophils in BAL ﬂuid compared to the naïve group.
The AMPH treatment in allergic rats (Allergic+AMPH group) increased
the number ofmacrophages and eosinophils compared to the rats of the
allergic group. Moreover, rats of the allergic+AMPH group presented
an increase in the number of lymphocytes, macrophages, neutrophils
and eosinophils when compared to the naive group (Panel B).
3.2. Quantiﬁcation of IL-4, IL-10 and TNF-α in the lung tissue of allergic
rats after chronic treatment with amphetamine
As seen in Fig. 2 (panel A), there were increased levels of IL-4 in the
allergic and allergic+AMPH groups compared to the naive group.
Moreover, the treatment with AMPH caused an additional increase in
IL-4 levels in relation to untreated rats (allergic group). On the other
hand, we observed, as shown in panel B, that treatment with AMPH in
Fig. 3. Expression of MAC-1 (A), ICAM-1 (B) and PCAM-1 (C) in the leukocytes present in the BAL of allergic rats treated or not treated with amphetamine. The expression of ad-
hesion molecules was determined by ﬂow cytometry 24 hours after OVA challenge. Data are the mean±SEM from 5 animals. ***pb0.001; **pb0.01 and *pb0.05 relative to allergic
group (ANOVA followed by Student–Newman–Keuls test).
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gic group. As seen in panel C, TNF-α concentrationsmeasured in the su-
pernatants of 24-h cultured lung tissue from the allergic group did not
differ from those observed in the allergic+AMPH group.
3.3. Evaluation of Mac-1, ICAM-1 and PECAM-1 expression after chronic
amphetamine treatment in allergic rats
As shown in Fig. 3 (panels A, B and C), AMPH treatment caused an
increase in Mac-1 expression (CD11b/CD18), ICAM-1 and PECAM-1 in
both cellular types (macrophages and granulocytes) compared to rats
not treated with AMPH (Allergic group).
3.4. Effects of long-term treatment with amphetamine on tracheal
reactivity to methacholine and anaphylaxis in vitro in allergic rats
As shown in Fig. 4 (panel A), the tracheal hyper-responsiveness to
MCh observed in the allergic group was reduced by treatment with
AMPH. Moreover, AMPH caused a reduction in tracheal reactivity toMCh relative to the naive group. In panel B, we can observe that treat-
ment with AMPH did not alter the tracheal reactivity induced by OVA
challenge in vitro.
3.5. Effects of long-term amphetamine treatment on mast cells
degranulation after OVA challenge
As shown in Fig. 5 (panels A, B and C), long-termAMPH treatment did
not modify mast cells degranulation in allergic rats, as the number (Panel
B) and the percentage of mast cells degranulated (Panel C) was similar
between the allergic and allergic+AMPHgroups.Moreover,we observed
that allergic rats treated or not treated with AMPH presented an increase
number inmast cells degranulation (Panel B) as well as of the percentage
of degranulation (Panel C) when compared to the naive group.
4. Discussion
AMPH is an abused drug that exerts effects on the immunological
systems [18,5] and, modulates the course of allergic lung response
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Fig. 4. Tracheal responsiveness to methacholine (MCh) (A) and antigen speciﬁc response
(B) in allergic rats treated by long-term with amphetamine. Groups of rats were treated or
not treated with AMPH during 21 days and sensitized with OVA one week after the ﬁrst
treatments (AMPH or vehicle). Seven days after, the rats were challengedwith OVA by aero-
sol. The non-manipulated rats were used as controls (naive group). Tracheal rings were
maintained in the organ bath system and the contractile responses to MCh were recorded.
Anaphylactic reactionsweredeterminedby additionofOVA(4 mg/ml) in theorganbath sys-
tem. Data are the mean±SEM from 5 animals. *pb0.05 relative to naïve group and pb0.05
relative to allergic group (ANOVA followed by Student–Newman–Keuls test).
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tentiates the allergic lung inﬂammation by adhesion molecules ex-
pression and cytokines release mediated-mechanism. In parallel,
reduces the tracheal hyper-responsiveness to cholinergic stimulus
(methacholine).
We conﬁrmed in the present study that treatment with AMPH for
21 days increased leukocyte inﬁltration into the lungs, as demonstrated
by an elevated number of macrophages and eosinophils. In contrast to
what we observed concerning the increase in allergic lung inﬂamma-
tion after long-term AMPH treatment, we have reported in other stud-
ies, using an experimental asthma model, that single AMPH treatment
from 12 h before OVA challenge down-regulates several parameters
of allergic lung inﬂammation, including cellularmigration, vascular per-
meability and tracheal hyper-responsiveness to methacholine (MCh).
Moreover, we also demonstrated that the reduced lung inﬂammation
induced by acute AMPH treatment (before OVA challenge) might not
be attributable to a direct effect of this drug, but due to a corticosterone
action on bone marrow activity [7]. Interestingly, corticosterone serum
levels measured in these AMPH repeated treated rats were statistically
similar to those of their respective controls [6]. Thus, we can infer that
after repeated AMPH treatment, the corticosterone levels return to
basal levels suggesting an adaptive mechanism that can contribute to
the development of the allergic lung response.
Cytokines, including IL-4 and IL-10 are critical in inﬂammatory dis-
ease, contributing to the recruitment and activation of inﬂammatory leu-
kocytes. These cytokines are produced in abundance by activated CD4þ
Th2 cells, mast cells, eosinophils and, basophils. Alternatively, activated
alveolar macrophages also release substantial amounts of IL-4 [19,20].
IL-4 induces production of IgE antibodies and increases bronchial respon-
siveness, while IL-10 causes suppression of mast cell and eosinophil ac-
tivity [21,22].In the present study, we observed elevated levels of IL-4 and re-
duced levels of IL-10 after treatment with the AMPH, a phenomenon
that coexisted with increased cells inﬂux into the lung. On the other
hand, TNF levels did not modify by AMPH treatment. Thus, we sug-
gest that a high level of IL-4 associated with a low level of IL-10
might have contributed to cell mobilization into the lung in allergic
rats after AMPH treatment. Overall, these data might indicate that
AMPH alters the endogenous control of inﬂammatory response.
Leukocyte migration into inﬂamed tissues involves complex inter-
actions of leukocytes with the endothelium through regulated ex-
pression of surface adhesion molecules. ICAM-1 and PECAM-1 are
well established as molecules involved in neutrophil, macrophage
and lymphocyte vascular transmigration [23,24]. The integrin αMβ2
(Mac-1) is expressed on the surface of many leukocytes involved in
the innate immune system, including monocytes, granulocytes, mac-
rophages, and natural killer cells [25]. We demonstrated that
long-term AMPH treatment increases cellular expression of Mac-1,
ICAM-1 and PECAM-1, a fact that could justify the augmented allergic
inﬂammatory response after OVA challenge.
Cholinergic bronchial hyper-responsiveness can be observed in
eosinophil-mediated lung inﬂammation models [26,27]. In this context,
it was interesting to ﬁnd that a signiﬁcant lung inﬂammation elicited
by long-term AMPH treatment coexisted with a reduction in tracheal
hyper-responsiveness. In fact, other studies demonstrated that inﬂam-
matory events (pulmonary cell inﬂux) can be dissociated from those
governing the bronchial smooth muscle tonus (hypo-responsiveness)
[28]. Moreover, similar to the result of a recent study of our group, we
demonstrated that single AMPH treatment 12 h before anOVA challenge
also reduced tracheal hyper-responsiveness toMCh [11]. AMPHexerts its
effects on peripheral and central catecholamine neurotransmitter sys-
tems, which play a key role in the high abuse potential of this drug. The
molecular products of nervous and immune system cells provide a
means of communication between these two systems and constitute
what is currently being investigated in the neuroimmunomodulation
ﬁeld [29,30]. Within this context, AMPH has been shown to modulate
asthma through neuronal (adrenergic) and endocrine (corticosterone)
mediation [6,7]. It is reasonable to admit that the tracheal hypo-
responsiveness observed in our studies could be related to the release
of catecholamines, which are known to exert relaxant effects on the air-
ways smooth muscle by acting on the beta 2 adrenergic receptors [31].
As the long-term AMPH treatment began before the OVA sensiti-
zation, we investigated whether the effect induced by AMPH on
lung inﬂammation could correlate to changes in the synthesis of
anaphylactic immunoglobulin. Our results indicated that AMPH treat-
ment did not alter tracheal responsiveness to the OVA challenge
in vitro, indicating that AMPH did not interfere with antibody
generation.
Mast cells exert a pivotal role on airway responsiveness caused by
allergic disorders [32]. Moreover, recent studies of our group found
that OVA-induced tracheal hypo-responsiveness might explain the
regulation of AMPH on mast cell degranulation without modiﬁcations
to anti-OVA IgE synthesis [11]. Our previous data suggest that the
treatment with AMPH decreased the percentage of mast cells that
presented degranulation, as indicated by lower activation and release
of the cytoplasmic granules [11]. In contrast, in the current work, we
demonstrated that allergic rats treated long-term or not with AMPH
presented a similar percentage of mast cells degranulation. Thus, we
can infer that the increase in lung inﬂammation and the decrease in
tracheal reactivity observed after long-term AMPH treatment might
not be attributed to changes in activation of mast cells. Indeed, the
percentage of mast cells degranulated in both groups (allergic and
allergic+AMPH) was similar.
In conclusion, our ﬁndings suggest that lung inﬂammation and upper
airway reactivity due to OVA-challenge are under the distinct control of
this long-term AMPH treatment. Thus, AMPH treatment increases aller-
gic lung inﬂammation and reduces the tracheal responsiveness. Our
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Fig. 5. Mast cell degranulation in lung tissue after long-term amphetamine treatment. Quantitative analysis of histological lung sections presenting intact (arrows) and
degranulated mast cells (arrowheads). The naïve group presenting intact mast cells, while the allergic and allergic+AMPH groups present degranulated mast cells in the lung pa-
renchyma as evidenced by metachromatic granules in the extracellular matrix (Panel A). In panel B, the number of mast cells and in panel C the percentage of degranulation are
presented. Toluidine blue stain. Bar: 5 μm. Data are the mean±SEM from 5 animals. *pb0.05 relative to naïve group (ANOVA followed by Student–Newman–Keuls test).
528 A.P. Ligeiro de Oliveira et al. / International Immunopharmacology 14 (2012) 523–529data strongly indicate that the effect of AMPH on the lung inﬂammatory
response involves an increase in ICAM-1, PECAM-1,Mac-1 and IL-4 and a
decrease of IL-10. Therefore, individuals that abuse drugs, such as am-
phetamines, aremore sensitive to the development of an allergic lung re-
sponse, presenting a serious health public problem.
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